{"id":4772,"date":"2014-11-02T13:25:58","date_gmt":"2014-11-02T12:25:58","guid":{"rendered":"http:\/\/www.fedaiisf.it\/?p=4772"},"modified":"2014-11-04T12:11:43","modified_gmt":"2014-11-04T11:11:43","slug":"farmaci-equivalenti-sfiducia-parte-dei-farmacisti-i-dati-studio-doxa","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/farmaci-equivalenti-sfiducia-parte-dei-farmacisti-i-dati-studio-doxa\/","title":{"rendered":"Equivalent drugs: distrust from pharmacists, data from the Doxa study"},"content":{"rendered":"

by\u00a0<\/i>Lentano Ciro November 1, 2014 \u2013 quelchefarmacia magazine<\/a><\/i><\/p>\n

\"\"Between<\/a> the\u00a0health policies<\/b>\u00a0aimed at saving costs, also in the international arena, the frequent use of\u00a0drugs<\/a>\u00a0equivalent<\/a>\u00a0represents one of the primary policies, so much so that it has pushed for the definition of the legislation which since 2012, as a legal obligation, forces pharmacists to present the generic analogue of a branded medicine to the user. Although we often talk about conveniences for the class of pharmacists, in reality it is\u00a0Doxa study<\/b>\u00a0would reveal a paradoxical and contrary situation with the\u00a0professionals<\/a>\u00a0inclined to favor the branded for safety issues\u00a0bioavailability<\/b>\u00a0and therapeutic efficacy.<\/p>\n

The situation would obviously be the result of the scarce information campaigns that on the comparison between\u00a0drugs<\/a>\u00a0equivalent<\/a><\/b>\u00a0and branded have failed to provide an adequate level of ed education\u00a0information<\/a>\u00a0to users, who have however shown themselves to be equally careful to evaluate the impact with their own means. In particular,\u00a0data<\/a>\u00a0in hand, the Italians are now more and more convinced of the usefulness of the biosimilar so much that the 92% makes constant use of it and the 80% declares itself satisfied with the service and quality provided in the therapeutic field. Although i\u00a0data<\/a>\u00a0the study is growing, which has also addressed the evaluation and professional consideration of\u00a0pharmacists<\/b>, a greater orientation towards the would emerge\u00a0branded<\/b>, capable of providing greater guarantees in terms of release and share of\u00a0active principle<\/a>\u00a0available, as confirmed by\u00a0data<\/a>\u00a0of exchange dropped from the 58% of 2012 to the 53% of 2013.<\/p>\n

She intervened on the matter, expressing her opinion,\u00a0Pia Policicchio<\/i>\u00a0who explained how much on\u00a0equivalent drugs\u00a0<\/a>there was bad conduct\u00a0information campaign<\/a>\u00a0capable of generating complex beliefs to be eradicated, on which the greatest perplexities are based, although the comparison with the\u00a0Healthcare systems<\/b>\u00a0foreign<\/a>\u00a0now become synonymous with quality is helping to strengthen and improve the image of\u00a0generics<\/b>, the latter in which their use is strongly consolidated: \u201c\u2026there was talk of generic<\/i>\u00a0\u2013 explained the president of Fenagifar \u2013 \u00a0as an economic alternative without dwelling on the therapeutic response and the need to give the public certainties of equivalence with respect to the originator\u00bb. From here perhaps die-hard convictions arose<\/i>\u201c.<\/p>\n

\u2013 See more at: http:\/\/quellichelafarmacia.com\/19035\/farmaci-equivalenti-sfiducia-parte-dei-farmacisti-i-dati-studio-doxa\/#.VFX5QvmG98E<\/a><\/p>\n

Prevention and equivalent medicines: behaviors in support of sustainability<\/span><\/h1>\n

By\u00a0Except Francina<\/a>\u00a0on October 30, 2014 \u2013 Liquidarea.com<\/a><\/p>\n

\"\"A Doxa survey, commissioned by Teva Italia, was presented today in Milan, which highlights the spontaneous perception of the concept of personal and civil responsibility of Italians when it comes to a more sustainable system of care. And the need for more and more correct information.<\/strong><\/p>\n

Milan, October 30, 2014\u2013<\/strong>\u00a0The historical era in which we live is certainly not the easiest: the particular economic situation has determined the need to pay greater attention to the issue of\u00a0sustainability<\/a>. If we talk about Health, then, the mechanism becomes even more complicated because the concept of\u00a0sustainability<\/a>\u00a0it declines not only in the representation of "savings of the public system", but also in that of "personal advantage". The Italians identify in the\u00a0\u201cprevention<\/a>\u201d<\/strong>\u00a0and in the use of\u00a0\u201cdrugs<\/a>\u00a0equivalent<\/a>\u201d<\/strong>two\u00a0effective tools to combat waste and guarantee the National Health Service\u00a0sustainability<\/a>\u00a0and efficiency<\/strong>.<\/p>\n

To say the qualitative\/quantitative survey of\u00a0Doxa,"Sustainability<\/a>of treatments, who is responsible?\u201d, presented today in Milan and commissioned by Teva Italia<\/strong>, a leading company in the pharmaceutical sector, which has always been committed to making high-quality care accessible through the development, production and marketing of both\u00a0equivalent<\/a>\u00a0both of\u00a0drugs<\/a>\u00a0innovative, pharmaceutical specialties and active ingredients.<\/p>\n

The research examined a sample made up of 600 subjects, men and women aged between 18 and 64 years. The results showed that there are mainly four attitudes among Italians referring to\u00a0sustainability<\/a>\u00a0of care: the figure of\u00a0\u201cparticipatory\u201d<\/strong>, or the one who optimistically believes he can "do a lot through his own attitude and daily behavior", that of the"angry"<\/strong>who believes "that they are already doing a lot through taxes and who expect a greater commitment from doctors, pharmacists and institutions", the\u201dself-indulgent\u201d<\/strong>, convinced "that I can do very little as an individual" and the"fatalistic"<\/strong>, \u201cconvinced that \u201cit is useless to bother looking for solutions because in the Italian system things never change\u201d. It is very important to highlight explainsMassimo Sumberesi, Managing Director of Doxa Marketing Advice\u00a0<\/strong>that among these archetypes, it is not only the participatory who has an active role, but in some way also the angry, although his energies are concentrated in the invective and are hetero-referred\u201d. He continues: "In contrast, the self-indulgent and fatalist have a passive and pessimistic attitude, justifying themselves and\/or generally blaming the system for malfunctioning." He adds: "With the exception of participatory participants, the tendency to identify responsibility for what does not work in third parties prevails".<\/p>\n

In general, however, the Italians believe that the\u00a0"wasting of resources by the public administration" (64%), the "poor social equity" (63%) and the "opportunism and lack of honesty of those in power" (59%) are the main threats to\u00a0sustainability<\/a>\u00a0of the system.<\/strong>\u00a0In fourth place we also find \u201cthe high cost of\u00a0drugs<\/a>\u201d. \u201cThis is an aspect that directly involves pharmaceutical companies,\u201d he saysHubert Puech d'Alissac, CEO of Teva Italy\u00a0<\/strong>"in reality, it should be emphasized that the scientific progress recorded in the last 50 years has been enormous and often possible thanks to the commitment and resources invested by the pharmaceutical industry". He continues: \u201cIn addition, the companies that produce\u00a0drugs<\/a>\u00a0equivalent<\/a>, have been able to save the Italian health system \u20ac1.5 billion in the last 6 years. Teva in particular is an example of a reality that, in addition to making treatments with i\u00a0drugs<\/a>\u00a0equivalent<\/a>\u00a0continues to engage and invest in research and development to create new therapeutic solutions and innovative specialty products.\u201d<\/p>\n

Just the use of\u00a0drugs<\/a>\u00a0equivalent<\/a>\u00a0it was then indicated by the sample as one of the "virtuous behaviours" to guarantee more accessible treatments for all. 29% of the interviewees thinks so, while 38% believes that "the health authorities should carry out more checks on the SSN" and 30% that "a greater\u00a0prevention<\/a>, especially if we are talking about certain diseases\u201d.<\/strong><\/p>\n

Italians, in particular, are asking for more information on the equivalent drug: although the trend in the consumption of generics is growing,\u00a026% of the sample interviewed claims "that he has never talked about it with his own doctor"<\/strong>Pharmacies are not doing better: in fact, compared to 2013, the percentage of pharmacists (from 58 to 53%) who "often or with a certain frequency" propose the replacement of the brand name with its equivalent has dropped.<\/p>\n

In general, however, compared to last year, the dissemination and, therefore, the culture relating to\u00a0drugs<\/a>\u00a0equivalent<\/a>\u00a0has not recorded substantial variations, and therefore a strong awareness on the part of the institutions becomes important.<\/p>\n

Indeed, it is no coincidence that the Doxa survey highlights how citizens believe that all the players in the health system - citizens, patients, family doctors, specialists and pharmacists - need more information, which must be provided from different sources according to of the person involved.<\/p>\n

For example, both general practitioners and pharmacists should receive correct information mainly from "hospital structures and local health authorities", "government and political bodies" and "local public administrations".<\/p>\n

\u201cThe survey shows that there are still many misconceptions about\u00a0drugs<\/a>\u00a0with a generic name and that, therefore, a lot of information is still needed\u201d, he explains\u00a0Silvio Garattini, scientist and researcher<\/strong>\u00a0in pharmacology, director of the \u201cMario Negri\u201d Institute for Pharmacological Research.<\/p>\n

Agree with him too\u00a0Giuseppe Nielfi, president of the Single Union of Italian Outpatient Medicine and Healthcare Professionalism (SUMAI)<\/strong>: \u201cAdequate information is increasingly needed at all levelsto overcome prejudices e<\/strong>\u00a0so that news not complete or even\u00a0wrong<\/strong>\u00a0do not negatively impact the health of citizens and the work of white coats". And he adds: \u201cWith the diffusion of information 2.0,\u201d continues \u201cDoctor Web\u00a0it is stated<\/strong>\u00a0increasingly\u00a0as<\/strong>\u00a0first referent of\u00a0patients<\/strong>\u00a0of all ages\u00a0and as a vehicle for the training of health professionals.<\/strong>\u201d<\/p>\n

\u201cThe role of the pharmacist is an essential role to guarantee\u00a0prevention<\/a>\u00a0and accessibility to\u00a0drugs<\/a>\u00a0on the territory\u201d he confirms\u00a0Claudio Di Stefano, past president of the National Federation of Young Pharmacists Association (Fenagifar)<\/strong>"However, our commitment is not always sufficient: in fact, guidelines and tools capable of protecting the pharmacist's work day after day must be dictated at a central level".<\/p>\n

Finally, for citizens, it is not only the institutions that have to guarantee greater information, but they want to receive it above all from family doctors (65%), pharmacists (24%) and from the media (34%).<\/p>\n

TEVA<\/em><\/strong>
\nTeva Pharmaceutical Industries Ltd. (NYSE: TEVA) is one of the world's leading pharmaceutical companies. It is committed to increasing access to quality healthcare through the development, manufacturing and marketing of\u00a0drugs<\/a>\u00a0affordable generics, as well as of\u00a0drugs<\/a>\u00a0innovative and specialty products and active pharmaceutical ingredients. Based in Israel, Teva is the largest manufacturer of\u00a0drugs<\/a>\u00a0equivalent<\/a>\u00a0in the world, with a global product portfolio of over 1,000 molecules and a direct presence in around 60 countries. As for i\u00a0drugs<\/a>\u00a0innovations, Teva focuses its development activities in the areas of neurological diseases, pain, oncology, respiratory diseases and women's health, as well as in the area of\u00a0drugs<\/a>\u00a0biotechnology and biosimilars. Teva employs approximately 45,000 people worldwide and reported $20.3 billion in net revenues in 2013.<\/em><\/p>\n

\u00a0<\/span><\/h1>\n
\n

Generics bring down pharmacy profits<\/span><\/h1>\n<\/header>\n
\n
\n
\n
\n
\n
\n

MONDAY NOVEMBER 3, 2014, healthdesk<\/span><\/a><\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n

\n
\n
\n
\n
\n
\n

Profits of Italian pharmacists down, even if only slightly. In the first nine months of 2014, compared to the same period last year, Italian pharmacies recorded a loss of 0.3% in turnover against an increase in consumption of 0.9%.<\/p>\n

A trifle, except that it seems the first step in a trend destined to consolidate. The average values, in fact, hide a datum of particular interest. The profits of branded drugs decreased (mutable ones by 2.9% and non-borrowable ones by 2.1%), but those deriving from generics grew by almost 8%.<\/p>\n

Another trend is the shift of pharmacy profits from the actual drug to what is defined as the commercial area: non-prescription drugs but above all parapharmaceuticals. In this sector, dietetic foods grew by +5% thanks to the driving force of supplements, phytotherapy rose by +7.6% and veterinary by +8%.<\/p>\n

The data is contained in a survey of 5,000 pharmacies conducted by New Line Ricerche di Mercato.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/article>\n<\/div>\n<\/div>\n

<\/h1>","protected":false},"excerpt":{"rendered":"

by\u00a0Lentano Ciro novembre 1, 2014 \u2013 quellichelafarmacia magazine Tra le\u00a0politiche sanitarie\u00a0rivolte al risparmio di spesa, anche in campo internazionale, l\u2019utilizzo frequente di\u00a0farmaci\u00a0equivalenti\u00a0rappresenta una delle politiche primarie tanto d\u2019aver spinto alla definizione della normativa che dal 2012, come obbligo di legge, costringe i farmacisti a dover presentare all\u2019utente l\u2019analogo generico di un medicinale branded. Nonostante si …<\/p>","protected":false},"author":4,"featured_media":4776,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[31],"class_list":["post-4772","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizie","tag-generici"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/4772","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=4772"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/4772\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/4776"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=4772"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=4772"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=4772"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}